August 18, 2017 2:34 PM ET

Healthcare Providers and Services

Company Overview of Hackensack University Medical Center

Company Overview

Hackensack University Medical Center operates as a nonprofit teaching and research hospital that provides inpatient and outpatient services in New Jersey. The company offers emergency services, such as pediatric emergency, trauma, emergency preparedness, EM residency, family-centered care, mobile acute care hospital, mobile intensive care unit, and observation unit; and hospital services, including bioethics, communications and public relations, health information, information and guest services, medical physics, nutrition and food management, occupational therapy, pastoral care, pathology, inpatient and outpatient pharmacy, physical therapy, radiology, security, social service, speech thera...

30 Prospect Avenue

Hackensack, NJ 07601

United States

Founded in 1888





Key Executives for Hackensack University Medical Center

Chief Executive Officer, President, Member of Board of Governors and Member of Advisory Board
Chief Financial Officer and Executive Vice President
Age: 56
Executive Vice President of Patient Care Division and Chief Nursing Officer
Chairman of Orthopedic Surgery Department
Age: 65
Chairman of Anesthesiology Department and Member of Advisory Board
Compensation as of Fiscal Year 2017.

Hackensack University Medical Center Key Developments

Hackensack University Medical Center Presents at Premier Annual Breakthroughs Conference and Exhibitions 2017, Jun-27-2017 through Jun-30-2017

Hackensack University Medical Center Presents at Premier Annual Breakthroughs Conference and Exhibitions 2017, Jun-27-2017 through Jun-30-2017. Venue: Walter E. Washington Convention Center, 801 Mount Vernon Pl NW, Washington, DC 20001, United States. Presentation Date(s): Jun-28-2017. Jun-29-2017.

Hackensack University Medical Center Announces Clinical Trial Suggests Value of Venetoclax Combination Therapy in Patients with B-Cell Non-Hodgkin Lymphoma

A new global multi-center study co-authored by John Theurer Cancer Center (JTCC) at Hackensack University Medical Center researchers and presented here on June 6, 2016 at the American Society of Clinical Oncology (ASCO) annual meeting concludes that venetoclax, a selective, potent oral BCL-2 inhibitor with activity in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) in combination with standard therapeutic regimens, was well-tolerated and provides evidence of its potential therapeutic value in this patient population. The open-label, dose-finding trial, "Phase 1b study of Venetoclax Plus R- or G-CHOP in Patients with B-cell Non-Hodgkin Lymphoma," (Abstract No. 7566, Poster no. 122) evaluated a regimen used commonly in the treatment of NHL known as CHOP (Cyclophosphamide, Hydroxydaunomycin, Oncovin, Prednisone) in combination with either rituximab or obinutuzumab, to which venetoclax was added. Previous studies in NHL xenograft models have shown that venetoclax may enhance efficacy of rituximab plus CHOP (R-CHOP), or obinutuzumab plus CHOP (G-CHOP) therapies. This study sought to assess safety and tolerability of venetoclax in combination with R-CHOP or G-CHOP in patients with no more than one previous course of therapy and to determine the maximum tolerable dose (MTD) and define appropriate dose of venetoclax for a subsequent Phase 2 study and assess optimal therapeutic benefit. Primary outcome measures for the study are incidence of dose-limiting toxicities and complete response (CR) as defined by PET/CT scan and bone marrow examination. The expected study completion date is April 2018. As of November 30, 2015, 46 patients were enrolled in four cohorts and divided into two arms – rituximab plus CHOP (Arm A) and obinutuzumab plus CHOP (Arm B). Patients in cohort 1 received venetoclax 200-800 mg on cycle 1, day 4, and then daily for 8 cycles. In cohorts 2-4, patients received venetoclax on cycle 1, days 4-10 and cycles 2-8, days 1-10. CHOP was administered for six 21-day cycles. Rituximab was given on day 1 of cycles 1-8 (Arm A), while obinutuzumab was given on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-8 (Arm B). The most grade common adverse events were nausea (48%), fatigue (41%), and diarrhea (41%), and the most common grade 3-4 adverse events were neutropenia (37%) and febrile neutropenia (26%). Researchers determined that venetoclax combined with R- or G-CHOP was well-tolerated, and concluded that the appropriate dose for a Phase 2 study combining venetoclax with R-CHOP was 800mg on cycle 1, days 4-10 and cycle 2-8, days 1-10. Dose finding for venetoclax plus G-CHOP dose finding is ongoing, according to the investigators, who will present their latest findings during the ASCO meeting.

Hackensack University Medical Center Partners with CNOW to Launch Innovative Telehealth Pilot

CNOW announced strategic partnership with Hackensack University Medical Center. CNOW's telehealth solutions will effectively allow HackensackUMC's medical staff to connect with patients receiving psychiatric care through real-time, interactive video visits in the hospital, to the home, or anywhere services need to be delivered at any time.

Similar Private Companies By Industry

Company Name Region
@ Home Medical, Inc. United States
@home approach, llc United States
@Home Care United States
1011 E. Pecan Grove Road, LLC United States
1104 Welsh Road Operations LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Hackensack University Medical Center, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at